Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 111

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 111
---
 to form a complete family. According to CIC, because of the fertility
rate and recent government incentive policies, such as the Three-child Policy of China in 2021, the ARS market increased significantly
in Asia Pacific. Leveraging its status as a long-standing ARS provider in Asia Pacific, NewGenIvf expects to continue to be well positioned
to capture the expected growth in the demand for ARS in the area.

As of the date of this prospectus,
NewGenIvf owns and uses MicroSort technology in Thailand and Cambodia, which is a form of pre-conception gender selection technology for
humans. While NewGenIvf expects to benefit from first-mover advantages for this technology in the two regions, market entry by potential
competitors or faster-than-expected development of potential competitors may affect its market position and demand for its services and
cause downward pricing pressure on its treatments, which may in turn materially and adversely affect its results of operations. Meanwhile,
ARS market could also be affected by the macroeconomic environment and geopolitical events. Uncertainty in the macroeconomic environment,
resulting from a range of events and trends, including the rise in global inflation and interest rates, supply chain disruptions, geopolitical
pressures, including the unknown impact of current and future trade regulations, changes in Asian-Pacific relations, fluctuation in foreign
exchange rates, and associated global economic conditions may result in volatility in ARS market and NewGenIvf’s operating performance.
For example, NewGenIvf derives a substantial portion of its revenue from Chinese clients and as such, its failure to maintain PRC-sourced
revenues and access to new and existing clients from the PRC could materially and adversely affect its results of operations and competitive
position. However, the near-term growth prospects of the PRC economy are unclear due to the uncertain effects of ongoing economic stress
caused by policies to contain the COVID-19 pandemic, trade and national security policies, and the elevated levels of private and public
indebtedness, among others. According to the National Statistics Bureau of the PRC, growth rate of China’s GDP for the year 2022
slowed down to 3.0% on a year-on-year basis compared to the growth rate of approximately 8.4% for the year 2021. In the second quarter
of 2023, China’s GDP grew only 0.8% on a quarter basis, a significant slowdown from the 2.2% quarter growth registered